NIKKEI 225
37,789.39 -670.69 (-1.74%) HANG SENG
17,263.42 +62.15 (+0.36%) CRUDE OIL
82.66 -0.15 (-0.18%) GOLD FUTURES
2,331.80 -6.60 (-0.28%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,523.70 -2,012.95 (-3.76%)
Silence Therapeutics plc (SLN)
After hours:
| Previous close | 22.51 |
| Open | 22.49 |
| Bid | 22.23 x 200 |
| Ask | 22.50 x 100 |
| Day's range | 22.11 - 22.61 |
| 52-week range | 4.84 - 27.72 |
| Volume | |
| Avg. volume | 234,604 |
| Market cap | 1.108B |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
LONDON, April 08, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association (JAMA), linked her
- Business Wire
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
LONDON, March 13, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.
- Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
LONDON, March 13, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (
